Literature DB >> 26295640

Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology.

Stephanie Channual1, Nelly Tan1, Surachate Siripongsakun2, Charles Lassman3, David S Lu1, Steven S Raman1.   

Abstract

OBJECTIVE: The objective of our study was to determine quantitative differences to differentiate low-grade from high-grade dysplastic nodules (DNs) and low-grade from high-grade hepatocellular carcinomas (HCCs) using gadoxetate disodium-enhanced MRI.
MATERIALS AND METHODS: A retrospective study of 149 hepatic nodules in 127 consecutive patients who underwent gadoxetic acid-enhanced MRI was performed. MRI signal intensities (SIs) of the representative lesion ROI and of ROIs in liver parenchyma adjacent to the lesion were measured on unenhanced T1-weighted imaging and on dynamic contrast-enhanced MRI in the arterial, portal venous, delayed, and hepatobiliary phases. The relative SI of the lesion was calculated for each phase as the relative intensity ratio as follows: [mass SI / liver SI].
RESULTS: Of the 149 liver lesions, nine (6.0%) were low-grade DNs, 21 (14.1%) were high-grade DNs, 83 (55.7%) were low-grade HCCs, and 36 (24.2%) were high-grade HCCs. The optimal cutoffs for differentiating low-grade DNs from high-grade DNs and HCCs were an unenhanced to arterial SI of ≥ 0 or a relative SI on T2-weighted imaging of ≤ 1.5, with a positive predictive value (PPV) of 99.2% and accuracy of 88.6%. The optimal cutoffs for differentiating low-grade HCCs from high-grade HCCs were a relative hepatobiliary SI of ≤ 0.5 or a relative T2 SI of ≥ 1.5, with a PPV of 81.0% and an accuracy of 60.5%.
CONCLUSION: Gadoxetate disodium-enhanced MRI allows quantitative differentiation of low-grade DNs from high-grade DNs and HCCs, but significant overlap was seen between low-grade HCCs and high-grade HCCs.

Entities:  

Keywords:  dysplastic nodule; gadoxetate disodium; hepatocellular carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26295640     DOI: 10.2214/AJR.14.12716

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  Quantitative Assessment of Liver Function Using Gadoxetate-Enhanced Magnetic Resonance Imaging: Monitoring Transporter-Mediated Processes in Healthy Volunteers.

Authors:  Leonidas Georgiou; Jeffrey Penny; Glynis Nicholls; Neil Woodhouse; François-Xavier Blé; Penny L Hubbard Cristinacce; Josephine H Naish
Journal:  Invest Radiol       Date:  2017-02       Impact factor: 6.016

Review 2.  Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology.

Authors: 
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

3.  Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).

Authors:  Ying Ding; Sheng-Xiang Rao; Wen-Tao Wang; Cai-Zhong Chen; Ren-Chen Li; Mengsu Zeng
Journal:  Cancer Imaging       Date:  2018-12-07       Impact factor: 3.909

4.  An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation.

Authors:  Jelena Djokic Kovac; Aleksandar Ivanovic; Tamara Milovanovic; Marjan Micev; Francesco Alessandrino; Richard M Gore
Journal:  Radiol Oncol       Date:  2021-01-29       Impact factor: 2.991

Review 5.  MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients.

Authors:  Riccardo Inchingolo; Riccardo Faletti; Luigi Grazioli; Eleonora Tricarico; Marco Gatti; Anna Pecorelli; Davide Ippolito
Journal:  World J Hepatol       Date:  2018-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.